{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:00:07Z","timestamp":1756191607916,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s40262-024-01467-z","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T14:54:41Z","timestamp":1734533681000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Relative Forgiveness of Different Allopurinol Implementation Patterns in People with Gout and their Impact on Clinical Outcomes: a Simulation Study"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5072-5489","authenticated-orcid":false,"given":"Melanie","family":"White-Koning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F. B.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dyfrig A.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni J. F.","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Coleshill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parisa","family":"Aslani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard O.","family":"Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2114-587X","authenticated-orcid":false,"given":"Sophie L.","family":"Stocker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"issue":"9","key":"1467_CR1","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1097\/00005650-200209000-00009","volume":"40","author":"M Robin DiMatteo","year":"2002","unstructured":"Robin DiMatteo M, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care. 2002;40(9):794. https:\/\/doi.org\/10.1097\/00005650-200209000-00009.","journal-title":"Med Care"},{"issue":"5","key":"1467_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","volume":"73","author":"B Vrijens","year":"2012","unstructured":"Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691\u2013705. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04167.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1467_CR3","volume-title":"Adherence to long-term therapies: evidence for action","author":"World Health Organisation","year":"2003","unstructured":"World Health Organisation. Adherence to long-term therapies: evidence for action. WHO; 2003."},{"issue":"8","key":"1467_CR4","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1136\/annrheumdis-2013-204647","volume":"73","author":"E Smith","year":"2014","unstructured":"Smith E, Hoy D, Cross M, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(8):1470\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204647.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1467_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10654-014-9927-y","volume":"30","author":"JMA Wijnands","year":"2015","unstructured":"Wijnands JMA, Viechtbauer W, Thevissen K, et al. Determinants of the prevalence of gout in the general population: a systematic review and meta-regression. Eur J Epidemiol. 2015;30(1):19\u201333. https:\/\/doi.org\/10.1007\/s10654-014-9927-y.","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"1467_CR6","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/acr.21772","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431\u201346. https:\/\/doi.org\/10.1002\/acr.21772.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"1467_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017542","volume":"8","author":"R Yin","year":"2018","unstructured":"Yin R, Li L, Zhang G, et al. Rate of adherence to urate-lowering therapy among patients with gout: a systematic review and meta-analysis. BMJ Open. 2018;8(4): e017542. https:\/\/doi.org\/10.1136\/bmjopen-2017-017542.","journal-title":"BMJ Open"},{"issue":"5","key":"1467_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","volume":"47","author":"LEJM Scheepers","year":"2018","unstructured":"Scheepers LEJM, van Onna M, Stehouwer CDA, Singh JA, Arts ICW, Boonen A. Medication adherence among patients with gout: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;47(5):689\u2013702. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.09.007.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"1467_CR9","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1002\/acr.22336","volume":"66","author":"MA De Vera","year":"2014","unstructured":"De Vera MA, Marcotte G, Rai S, Galo JS, Bhole V. Medication adherence in gout: a systematic review. Arthritis Care Res. 2014;66(10):1551\u20139. https:\/\/doi.org\/10.1002\/acr.22336.","journal-title":"Arthritis Care Res"},{"issue":"6","key":"1467_CR10","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.semarthrit.2021.09.003","volume":"51","author":"A Weisman","year":"2021","unstructured":"Weisman A, Tomlinson GA, Lipscombe LL, Perkins BA, Hawker GA. Allopurinol adherence, persistence and patterns of use in individuals with diabetes and gout: a retrospective, population-based cohort analysis. Semin Arthritis Rheum. 2021;51(6):1162\u20139. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.09.003.","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"1467_CR11","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1185\/03007990903017966","volume":"25","author":"R Halpern","year":"2009","unstructured":"Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis. Curr Med Res Opin. 2009;25(7):1711\u20139. https:\/\/doi.org\/10.1185\/03007990903017966.","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"1467_CR12","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3899\/jrheum.140588","volume":"42","author":"N Rashid","year":"2015","unstructured":"Rashid N, Coburn BW, Wu YL, et al. Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol. 2015;42(3):504\u201312. https:\/\/doi.org\/10.3899\/jrheum.140588.","journal-title":"J Rheumatol"},{"issue":"6","key":"1467_CR13","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3109\/14397595.2016.1170914","volume":"26","author":"S Lee","year":"2016","unstructured":"Lee S, So MW. Adherence with urate-lowering therapies among male patients with gout in a routine clinical setting. Mod Rheumatol. 2016;26(6):950\u20135. https:\/\/doi.org\/10.3109\/14397595.2016.1170914.","journal-title":"Mod Rheumatol"},{"issue":"3","key":"1467_CR14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.amjmed.2018.11.011","volume":"132","author":"TR Mikuls","year":"2019","unstructured":"Mikuls TR, Cheetham TC, Levy GD, et al. Adherence and outcomes with urate-lowering therapy: a site-randomized trial. Am J Med. 2019;132(3):354\u201361. https:\/\/doi.org\/10.1016\/j.amjmed.2018.11.011.","journal-title":"Am J Med"},{"issue":"3","key":"1467_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/art.20405","volume":"51","author":"A Shoji","year":"2004","unstructured":"Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321\u20135. https:\/\/doi.org\/10.1002\/art.20405.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"1467_CR16","first-page":"44","volume":"30","author":"E de Klerk","year":"2003","unstructured":"de Klerk E, van der Heijde D, Landew\u00e9 R, van der Tempel H, Urquhart J, van der Linden S. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout. J Rheumatol. 2003;30(1):44\u201354.","journal-title":"J Rheumatol"},{"issue":"9","key":"1467_CR17","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.pec.2018.04.009","volume":"101","author":"E M\u00e1rquez-Contreras","year":"2018","unstructured":"M\u00e1rquez-Contreras E, de L\u00f3pez Garc\u00eda-Ramos L, Martell-Claros N, et al. Validation of the electronic prescription as a method for measuring treatment adherence in hypertension. Patient Educ Couns. 2018;101(9):1654\u201360. https:\/\/doi.org\/10.1016\/j.pec.2018.04.009.","journal-title":"Patient Educ Couns"},{"issue":"1","key":"1467_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/jpepsy\/jsy062","volume":"44","author":"JM Plevinsky","year":"2019","unstructured":"Plevinsky JM, Wojtowicz AA, Miller SA, Greenley RN. Longitudinal barriers to thiopurine adherence in adolescents with inflammatory bowel diseases. J Pediatr Psychol. 2019;44(1):52\u201360. https:\/\/doi.org\/10.1093\/jpepsy\/jsy062.","journal-title":"J Pediatr Psychol"},{"issue":"1","key":"1467_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QAI.0000000000000548","volume":"69","author":"ML Petersen","year":"2015","unstructured":"Petersen ML, LeDell E, Schwab J, et al. Super learner analysis of electronic adherence data improves viral prediction and may provide strategies for selective HIV RNA monitoring. J Acquir Immune Defic Syndr 1999. 2015;69(1):109\u201318. https:\/\/doi.org\/10.1097\/QAI.0000000000000548.","journal-title":"J Acquir Immune Defic Syndr 1999."},{"issue":"3","key":"1467_CR20","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1007\/s10461-017-1724-7","volume":"22","author":"V Mudhune","year":"2018","unstructured":"Mudhune V, Gvetadze R, Girde S, et al. Correlation of adherence by Pill count, self-report, MEMS and plasma drug levels to treatment response among women receiving ARV therapy for PMTCT in Kenya. AIDS Behav. 2018;22(3):918\u201328. https:\/\/doi.org\/10.1007\/s10461-017-1724-7.","journal-title":"AIDS Behav"},{"issue":"7653","key":"1467_CR21","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1136\/bmj.39553.670231.25","volume":"336","author":"B Vrijens","year":"2008","unstructured":"Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114\u20137. https:\/\/doi.org\/10.1136\/bmj.39553.670231.25.","journal-title":"BMJ"},{"issue":"5","key":"1467_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1586\/17512433.2014.940896","volume":"7","author":"B Vrijens","year":"2014","unstructured":"Vrijens B, Urquhart J, White D. Electronically monitored dosing histories can be used to develop a medication-taking habit and manage patient adherence. Expert Rev Clin Pharmacol. 2014;7(5):633\u201344. https:\/\/doi.org\/10.1586\/17512433.2014.940896.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1467_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0169-409X(98)00029-5","volume":"33","author":"J Urquhart","year":"1998","unstructured":"Urquhart J. Pharmacodynamics of variable patient compliance: implications for pharmaceutical value. Adv Drug Deliv Rev. 1998;33(3):207\u201319. https:\/\/doi.org\/10.1016\/S0169-409X(98)00029-5.","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"1467_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/clpt.2010.171","volume":"88","author":"LG Osterberg","year":"2010","unstructured":"Osterberg LG, Urquhart J, Blaschke TF. Understanding forgiveness: minding and mining the gaps between pharmacokinetics and therapeutics. Clin Pharmacol Ther. 2010;88(4):457\u20139. https:\/\/doi.org\/10.1038\/clpt.2010.171.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1467_CR25","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1002\/cpt.1454","volume":"106","author":"D Hill-McManus","year":"2019","unstructured":"Hill-McManus D, Marshall S, Soto E, Hughes DA. Integration of pharmacometrics and pharmacoeconomics to quantify the value of improved forgiveness to nonadherence: a case study of novel xanthine oxidase inhibitors for gout. Clin Pharmacol Ther. 2019;106(3):652\u201360. https:\/\/doi.org\/10.1002\/cpt.1454.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1467_CR26","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2165\/00003088-199427030-00004","volume":"27","author":"J Urquhart","year":"1994","unstructured":"Urquhart J. Role of patient compliance in clinical pharmacokinetics: a review of recent research. Clin Pharmacokinet. 1994;27(3):202\u201315. https:\/\/doi.org\/10.2165\/00003088-199427030-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1467_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2165\/00003088-199732050-00001","volume":"32","author":"J Urquhart","year":"1997","unstructured":"Urquhart J. The electronic medication event monitor: lessons for pharmacotherapy. Clin Pharmacokinet. 1997;32(5):345\u201356. https:\/\/doi.org\/10.2165\/00003088-199732050-00001.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1467_CR28","doi-asserted-by":"publisher","first-page":"371","DOI":"10.2165\/00003088-200241050-00004","volume":"41","author":"P Nony","year":"2002","unstructured":"Nony P, Boissel JP. Use of sensitivity functions to characterise and compare the forgiveness of drugs. Clin Pharmacokinet. 2002;41(5):371\u201380. https:\/\/doi.org\/10.2165\/00003088-200241050-00004.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"1467_CR29","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/psp4.4","volume":"4","author":"P Assawasuwannakit","year":"2015","unstructured":"Assawasuwannakit P, Braund R, Duffull S. Quantification of the forgiveness of drugs to imperfect adherence. CPT Pharmacomet Syst Pharmacol. 2015;4(3):204\u201311. https:\/\/doi.org\/10.1002\/psp4.4.","journal-title":"CPT Pharmacomet Syst Pharmacol."},{"issue":"4","key":"1467_CR30","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/cpt.268","volume":"99","author":"P Assawasuwannakit","year":"2016","unstructured":"Assawasuwannakit P, Braund R, Duffull S. A framework for quantifying the influence of adherence and dose individualization. Clin Pharmacol Ther. 2016;99(4):452\u20139. https:\/\/doi.org\/10.1002\/cpt.268.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1467_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10928-022-09808-w","volume":"49","author":"NP McAllister","year":"2022","unstructured":"McAllister NP, Lawley SD. A pharmacokinetic and pharmacodynamic analysis of drug forgiveness. J Pharmacokinet Pharmacodyn. 2022;49(3):363\u201379. https:\/\/doi.org\/10.1007\/s10928-022-09808-w.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"1467_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10928-023-09897-1","volume":"51","author":"ED Clark","year":"2024","unstructured":"Clark ED, Lawley SD. How drug onset rate and duration of action affect drug forgiveness. J Pharmacokinet Pharmacodyn. 2024;51(3):213\u201326. https:\/\/doi.org\/10.1007\/s10928-023-09897-1.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1467_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16005","author":"DFB Wright","year":"2024","unstructured":"Wright DFB, Hishe HZ, Stocker SL, et al. The development and evaluation of dose-prediction tools for allopurinol therapy (Easy-Allo tools). Br J Clin Pharmacol. 2024. https:\/\/doi.org\/10.1111\/bcp.16005. (Published online February 15, 2024).","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1467_CR34","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/acr2.11666","volume":"6","author":"TJF Michael","year":"2024","unstructured":"Michael TJF, Wright DFB, Chan JS, et al. Patient-led urate self-monitoring to improve clinical outcomes in people with gout: a feasibility study. ACR Open Rheumatol. 2024;6(7):403\u201311. https:\/\/doi.org\/10.1002\/acr2.11666.","journal-title":"ACR Open Rheumatol."},{"issue":"8","key":"1467_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2165\/00003088-200746080-00001","volume":"46","author":"RO Day","year":"2007","unstructured":"Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46(8):623\u201344. https:\/\/doi.org\/10.2165\/00003088-200746080-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1467_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4615-9140-5_5","volume":"122A","author":"C Vitali","year":"1980","unstructured":"Vitali C, Pasero G, Clerico A, et al. Uric acid turnover in normals, in gout and in chronic renal failure using 14C-uric acid. Adv Exp Med Biol. 1980;122A:27\u201331. https:\/\/doi.org\/10.1007\/978-1-4615-9140-5_5.","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"1467_CR37","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","volume":"76","author":"LK Stamp","year":"2017","unstructured":"Stamp LK, Chapman PT, Barclay ML, et al. A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout. Ann Rheum Dis. 2017;76(9):1522\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210872.","journal-title":"Ann Rheum Dis"},{"key":"1467_CR38","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1080\/01621459.1963.10500845","volume":"58","author":"JH Ward Jr","year":"1963","unstructured":"Ward JH Jr. Hierarchical grouping to optimize an objective function. J Am Stat Assoc. 1963;58:236\u201344.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"1467_CR39","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/art.40381","volume":"70","author":"AL Gaffo","year":"2018","unstructured":"Gaffo AL, Dalbeth N, Saag KG, et al. Brief report: validation of a definition of flare in patients with established gout. Arthritis Rheumatol Hoboken NJ. 2018;70(3):462\u20137. https:\/\/doi.org\/10.1002\/art.40381.","journal-title":"Arthritis Rheumatol Hoboken NJ."},{"issue":"6","key":"1467_CR40","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40273-018-0642-5","volume":"36","author":"I Buchholz","year":"2018","unstructured":"Buchholz I, Janssen MF, Kohlmann T, Feng YS. A systematic review of studies comparing the measurement properties of the three-level and five-level versions of the EQ-5D. Pharmacoeconomics. 2018;36(6):645\u201361. https:\/\/doi.org\/10.1007\/s40273-018-0642-5.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1467_CR41","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40273-023-01243-0","volume":"41","author":"R Norman","year":"2023","unstructured":"Norman R, Mulhern B, Lancsar E, et al. The use of a discrete choice experiment including both duration and dead for the development of an EQ-5D-5L value set for Australia. Pharmacoeconomics. 2023;41(4):427\u201338. https:\/\/doi.org\/10.1007\/s40273-023-01243-0.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"1467_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1055\/s-0038-1651587","volume":"69","author":"FR Rosendaal","year":"1993","unstructured":"Rosendaal FR, Cannegieter SC, van der Meer FJ, Bri\u00ebt E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236\u20139.","journal-title":"Thromb Haemost"},{"key":"1467_CR43","unstructured":"R Core Team. R version 4.3.2. Published online 2023. https:\/\/www.R-project.org\/"},{"key":"1467_CR44","unstructured":"Kyle T Baron. mrgsolve: simulate from ODE-based models. Published online 2024. https:\/\/github.com\/metrumresearchgroup\/mrgsolve"},{"issue":"12","key":"1467_CR45","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.jval.2018.06.002","volume":"21","author":"D Hill-McManus","year":"2018","unstructured":"Hill-McManus D, Marshall S, Soto E, Lane S, Hughes D. Impact of non-adherence and flare resolution on the cost-effectiveness of treatments for gout: application of a linked pharmacometric\/pharmacoeconomic model. Value Health. 2018;21(12):1373\u201381. https:\/\/doi.org\/10.1016\/j.jval.2018.06.002.","journal-title":"Value Health."},{"issue":"9","key":"1467_CR46","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/ard.57.9.545","volume":"57","author":"F Perez-Ruiz","year":"1998","unstructured":"Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9):545\u20139. https:\/\/doi.org\/10.1136\/ard.57.9.545.","journal-title":"Ann Rheum Dis"},{"issue":"23","key":"1467_CR47","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1056\/NEJMoa050373","volume":"353","author":"MA Becker","year":"2005","unstructured":"Becker MA, Schumacher HR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450\u201361. https:\/\/doi.org\/10.1056\/NEJMoa050373.","journal-title":"N Engl J Med"},{"issue":"5","key":"1467_CR48","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3390\/antibiotics12050838","volume":"12","author":"N Carral","year":"2023","unstructured":"Carral N, Lukas JC, Estrad\u00e9 O, Jauregizar N, Morillas H, Su\u00e1rez E. Non-adherence in adult male patients with community-acquired pneumonia: relative forgiveness of amoxicillin versus respiratory fluoroquinolones. Antibiotics. 2023;12(5):838. https:\/\/doi.org\/10.3390\/antibiotics12050838.","journal-title":"Antibiotics"},{"key":"1467_CR49","unstructured":"FDA. US food and drug administration. Accessed Jul 15, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/009218s108lbl.pdf"},{"issue":"1","key":"1467_CR50","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1016\/S2665-9913(21)00319-2","volume":"4","author":"LK Stamp","year":"2022","unstructured":"Stamp LK, Frampton C, Morillon MB, et al. Association between serum urate and flares in people with gout and evidence for surrogate status: a secondary analysis of two randomised controlled trials. Lancet Rheumatol. 2022;4(1):e53\u201360. https:\/\/doi.org\/10.1016\/S2665-9913(21)00319-2.","journal-title":"Lancet Rheumatol."},{"issue":"12","key":"1467_CR51","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1007\/s10067-022-06416-4","volume":"41","author":"T Uhlig","year":"2022","unstructured":"Uhlig T, Karoliussen LF, Sexton J, et al. Fluctuation and change of serum urate levels and flares in gout: results from the NOR-Gout study. Clin Rheumatol. 2022;41(12):3817\u201323. https:\/\/doi.org\/10.1007\/s10067-022-06416-4.","journal-title":"Clin Rheumatol"},{"issue":"7","key":"1467_CR52","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1111\/bcp.15657","volume":"89","author":"JCJ Spragg","year":"2023","unstructured":"Spragg JCJ, Michael TJF, Aslani P, et al. Optimizing adherence to allopurinol for gout: patients\u2019 perspectives. Br J Clin Pharmacol. 2023;89(7):1978\u201391. https:\/\/doi.org\/10.1111\/bcp.15657.","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-024-01467-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-024-01467-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,25]],"date-time":"2025-01-25T09:51:34Z","timestamp":1737798694000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-024-01467-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1467"],"URL":"https:\/\/doi.org\/10.1007\/s40262-024-01467-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"27 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study conception and design: MWK, DFBW, SLS. Data acquisition and preparation: MWK, DFBW, DAH, TJFM, MJC, PA, ROD, SLS. Data analysis: MWK, DFBW, SLS. Simulations: MWK. The first draft of the manuscript was written by MWK, and all authors commented on data interpretation and the manuscript. All authors contributed to and approved the final manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"No funding was received for conducting this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing financial or non-financial interests to declare that are relevant to the content of this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"All R code used in this study is available as supplementary information.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}